NASDAQ:PCLA PicoCELA (PCLA) Stock Price, News & Analysis $6.50 -0.80 (-10.96%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$6.74 +0.25 (+3.77%) As of 06/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PicoCELA Stock (NASDAQ:PCLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PicoCELA alerts:Sign Up Key Stats Today's Range$6.50▼$7.6350-Day Range$1.35▼$12.0052-Week Range$1.35▼$112.20Volume21,633 shsAverage Volume4.44 million shsMarket Capitalization$260 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview PicoCELA, Inc. is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers. The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens. Preclinical studies have demonstrated robust neutralizing antibody titers and T-cell activation in animal models, supporting progression toward clinical trials. Beyond infectious disease, PicoCELA is exploring oncology applications in which tumor-associated antigens are presented on its nanoscaffold to stimulate a targeted immune attack against cancer cells. Founded in 2019 and headquartered in Connecticut, PicoCELA went public via a Nasdaq listing in 2021. The company collaborates with academic research centers and contract development organizations across the United States to advance its preclinical and future clinical-stage programs. PicoCELA’s leadership team comprises experienced executives and scientific founders with backgrounds in immunology, protein engineering and vaccine development, positioning the company to address unmet medical needs through its modular nanoparticle technology.AI Generated. May Contain Errors. Read More PicoCELA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScorePCLA MarketRank™: PicoCELA scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPicoCELA has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePicoCELA has only been the subject of 1 research reports in the past 90 days.Read more about PicoCELA's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPicoCELA has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted333.40% of the float of PicoCELA has been sold short.Short Interest Ratio / Days to CoverPicoCELA has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PicoCELA has recently increased by 1,375.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPicoCELA does not currently pay a dividend.Dividend GrowthPicoCELA does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.17 News SentimentPicoCELA has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PicoCELA this week, compared to 1 article on an average week.Search Interest1 people have searched for PCLA on MarketBeat in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PicoCELA insiders have not sold or bought any company stock.Percentage Held by InstitutionsPicoCELA has minimal institutional ownership at this time.Read more about PicoCELA's insider trading history. Receive PCLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PicoCELA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCLA Stock News HeadlinesPicoCELA Inc. (PCLA) Stock Forum & Discussion - Yahoo FinanceJune 9 at 7:13 PM | finance.yahoo.comPicoCELA Inc. American Depositary Shares (PCLA) Pre-MarketMay 28, 2026 | nasdaq.comThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain. | Behind the Markets (Ad)PicoCELA Inc. (PCLA) Stock Price, News, Quote & History - Yahoo FinanceMay 28, 2026 | finance.yahoo.comPicocela ADR Stock Price HistoryMay 23, 2026 | investing.comPicoCELA Stock Short Interest Report | NASDAQ:PCLA | BenzingaMay 17, 2026 | benzinga.comPicoCELA Shareholders Approve New Class A Preferred Shares and Charter Amendments at April EGMMay 12, 2026 | tipranks.comPicoCELA Inc. (PCLA) Unveils Game-Changing Wireless Mesh TechnologyMay 2, 2026 | insidermonkey.comSee More Headlines PCLA Stock Analysis - Frequently Asked Questions How have PCLA shares performed this year? PicoCELA's stock was trading at $9.06 at the beginning of the year. Since then, PCLA shares have decreased by 28.3% and is now trading at $6.50. When did PicoCELA's stock split? Shares of PicoCELA reverse split on Monday, January 26th 2026.A 1-30 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, January 25th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did PicoCELA IPO? PicoCELA (PCLA) raised $10 million in an IPO on Wednesday, January 15th 2025. The company issued 2,000,000 shares at $4.00-$6.00 per share. Benjamin Securities and Prime Number Capital acted as the underwriters for the IPO. How do I buy shares of PicoCELA? Shares of PCLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/09/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 2 weeks, PCLA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Electric Lighting & Wiring Equipment Sub-IndustryElectrical Equipment Current SymbolNASDAQ:PCLA CIK2018462 WebN/A Phone81 03-6661-2780FaxN/AEmployees53Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio2.13 Quick Ratio1.57 Sales & Book Value Annual Sales$3.64 million Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value$82.71 per share Price / Book0.08Miscellaneous Outstanding Shares40,000Free FloatN/AMarket Cap$260 thousand OptionableN/A Beta10.92 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PCLA) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PicoCELA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PicoCELA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.